Altamira Therapeutics Ltd.
CYTOF evidence brief
What we can confirm
- Market Cap:
- $286K
What it means
What to watch
Prepared research question
What matters most for CYTOF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CYTOF
Altamira Therapeutics Ltd. is a Bermuda-based company focused on developing and commercializing RNA delivery technology for targets beyond the liver, with a legacy product in nasal spray (Bentrio).
Key risk: Zero cash position
Market Cap
$286K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
Altamira Therapeutics Ltd. is a Bermuda-based company focused on developing and commercializing RNA delivery technology for targets beyond the liver, with a legacy product in nasal spray (Bentrio).
- Altamira is dedicated to developing and commercializing RNA delivery technology for targets beyond the liver [news · published 2026-04-13].
- The company reported cash & equivalents of $0.0M and shareholders' equity of $4.1M as of 2025-06-30 [sec].
- In 2024, cash used in operations more than halved, and the company finished the year with shareholders' equity of $6.6 million [news · published 2025-04-30].
- Altamira received allowance of a Japanese patent application covering Bentrio Nasal Spray in February 2026 [news · published 2026-02-13].
- The company plans to partially spin off its RNA delivery business [news · published 2025-04-30].
What works
- The company's RNA delivery technology is being developed for targets beyond the liver, which may address a broader range of diseases [news · published 2026-04-13].
- Cash used in operations more than halved in 2024, indicating improved cost management [news · published 2025-04-30].
- A Japanese patent allowance for Bentrio Nasal Spray provides intellectual property protection in a key market [news · published 2026-02-13].
What to weigh
- Cash & equivalents were $0.0M as of 2025-06-30, suggesting very limited liquidity [sec].
- Shareholders' equity declined from $6.6 million at end of 2024 to $4.1 million as of 2025-06-30, indicating ongoing cash burn [news · published 2025-04-30] [sec].
- The company's RNA delivery business is still in development and has not yet generated significant revenue from partnerships [news · published 2025-04-30].
From the filings
Quoted directly from source documents.
Company focus on RNA delivery beyond the liver
“a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver”
News · April 13, 2026
Cash used in operations halved in 2024
“Cash used in operations more than halved in 2024 - finished year with shareholders’ equity of $6.6 million”
News · April 30, 2025
Japanese patent allowance for Bentrio
“Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Bentrio Nasal Spray”
News · February 13, 2026
Plans to partially spin off RNA delivery business
“Plans to partially spin off RNA delivery business”
News · April 30, 2025
Risks & what to watch (3)›
Key risks
- Zero cash position — Cash & equivalents were $0.0M as of 2025-06-30, raising going-concern risk [sec].
- Declining shareholders' equity — Equity fell from $6.6M (end 2024) to $4.1M (mid-2025), indicating continued cash burn [news · published 2025-04-30] [sec].
- Early-stage RNA delivery business — RNA delivery platform is still in development with no clear revenue from partners yet [news · published 2025-04-30].
What to watch
- Progress of the planned partial spin-off of the RNA delivery business [news · published 2025-04-30].
- Any new partnership or licensing deals for the RNA delivery platform [news · published 2025-04-30].
- Commercialization or further patent developments for Bentrio Nasal Spray [news · published 2026-02-13].
- Next financial results and business update call scheduled for August 29, 2025 [news · published 2025-08-27].
Sources: Competitor trials · News · SEC filings · Generated October 3, 2026 · How we verify sources →
Run Altamira Therapeutics Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Altamira Therapeutics Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of May 20, 2026- % of float
- 1.4%
- Days to cover
- 0.5
- Shares short
- 50,630
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CYTOF short interestFrequently asked questions
What is the AI investment thesis for Altamira Therapeutics Ltd.?
Altamira Therapeutics Ltd. is a Bermuda-based company focused on developing and commercializing RNA delivery technology for targets beyond the liver, with a legacy product in nasal spray (Bentrio).
Who is the CEO of Altamira Therapeutics Ltd.?
Dr. Thomas Meyer Ph.D. is the chief executive officer of Altamira Therapeutics Ltd. (CYTOF).
Where is Altamira Therapeutics Ltd. headquartered?
Altamira Therapeutics Ltd. (CYTOF) is headquartered in Hamilton, Bermuda.
What therapeutic areas does Altamira Therapeutics Ltd. focus on?
Altamira Therapeutics Ltd. develops therapies across Ophthalmology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.